Dofetilide

Major

Dofetilide Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Dofetilide Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Dofetilide Revumenib Revuforj An increased risk of QT interval prolongation Details Dofetilide Ribociclib Kisqali Increased CYP3A4 substrates exposure, an increased risk of CYP3A4 substrate-related adverse reactions and an increased risk of QT... Details Dofetilide Rilpivirine Edurant An increased risk of QT interval prolongation and torsade de pointes Details Dofetilide Risperidone Perseris Increased risk of QT interval prolongation and an increased risk of torsades de pointes Details Dofetilide Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Dofetilide Ritonavir Norvir Increased dofetilide exposure and an increased risk of QT interval prolongation Details Dofetilide Selpercatinib Retevmo Increased substrate exposure, an increased risk of adverse reaction and an increased risk of QT interval prolongation Details Dofetilide Sertindole An increased risk of QT interval prolongation, and an increased risk of torsades de pointes Details Dofetilide Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Dofetilide Sevoflurane Petrem Increased risk of QT interval prolongation Details Dofetilide Siponimod Mayzent An increased risk of QT interval prolongation Details Dofetilide Sodium Phosphate OsmoPrep An increased risk of QT interval prolongation Details Dofetilide Sodium Phosphate, Dibasic An increased risk of QT interval prolongation Details Dofetilide Sodium Phosphate, Monobasic An increased risk of QT interval prolongation Details Dofetilide Solifenacin Vesicare An increased risk of QT interval prolongation Details Dofetilide Sorafenib Nexavar An increased risk of QT interval prolongation Details Dofetilide Sotalol Betapace Increased risk of QT interval prolongation or prolonged refractoriness Details Dofetilide Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Dofetilide Spiramycin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Sulpiride An increased risk of QT interval prolongation Details Dofetilide Sultopride An increased risk of QT interval prolongation, and an increased risk of torsades de pointes Details Dofetilide Sunitinib Sutent An increased risk of QT interval prolongation Details Dofetilide Suzetrigine Journavx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dofetilide Tacrolimus Astagraf An increased risk of QT interval prolongation Details Dofetilide Tafenoquine Arakoda Increased plasma concentrations of OCT2 and MATE substrates Details Dofetilide Taletrectinib Ibtrozi Increased risk of QT interval prolongation and torsade de pointes Details Dofetilide Tamoxifen Nolvadex® An increased risk of QT interval prolongation Details Dofetilide Taurursodiol Decreased exposure of the CYP3A4 substrate Details Dofetilide Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dofetilide Telaprevir Increased dofetilide exposure and an increased risk of QT interval prolongation Details Dofetilide Telavancin Vibativ Increased risk of QT interval prolongation Details Dofetilide Telithromycin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Tetrabenazine Xenazine Increased risk of QT interval prolongation Details Dofetilide Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Dofetilide Tolterodine Detrol An increased risk of QT interval prolongation Details Dofetilide Toremifene Fareston An increased risk of QT interval prolongation, ventricular tachycardia or an increased risk of torsade de pointes Details Dofetilide Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dofetilide Trazodone Raldesy An increased risk of QT interval prolongation and an increased risk of cardiac arrythmia Details